Abstract
Drug resistance remains a major clinical challenge for cancer treatment. One mechanism by which tumor cells develop resistance to cytotoxic agents and radiation is related to resistance to apoptosis. Apoptosis is a well-organised process of cell death pre-programmed inside the cell. Apoptosis can be initiated either by activation of death receptors on the cell surface membranes (extrinsic pathway) or through a series of cellular events primarily processed at mitochondria (intrinsic pathway). Apoptosis has been shown to be important for tumorigenesis and cancer treatment. Defects in apoptosis can result in the expansion of a population of neoplastic cells. However, because the death of tumor cells induced by chemotherapy and radiotherapy is largely mediated by activation of apoptosis, inhibition of apoptosis will make tumor cells resistant to anti-tumor treatment. Herein, we will review the molecular changes that have the potential to cause apoptotic dysregulation, including activation of antiapoptotic factors (Bcl-2, BCLXL, Bfl1/A1 etc.), inactivation of pro-apoptotic effectors (p53, p53 pathway), and /or reinforcement of survival signals (Survivin, FLIP, NF-κB etc). Furthermore, we will discuss therapeutic intervention and/or strategies that can lower the threshold for apoptosis of tumor cells that could became useful approaches to treat cancer with special emphasis placed on the important priority to develop new cancer therapeutics toward tumor stem cells.
Keywords: Apoptosis, Bcl-2, p53, TNFα, TRAIL, survivin, clinical trials
Current Cancer Drug Targets
Title: Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Volume: 9 Issue: 3
Author(s): Pepita Gimenez-Bonafe, Avelina Tortosa and Ricardo Perez-Tomas
Affiliation:
Keywords: Apoptosis, Bcl-2, p53, TNFα, TRAIL, survivin, clinical trials
Abstract: Drug resistance remains a major clinical challenge for cancer treatment. One mechanism by which tumor cells develop resistance to cytotoxic agents and radiation is related to resistance to apoptosis. Apoptosis is a well-organised process of cell death pre-programmed inside the cell. Apoptosis can be initiated either by activation of death receptors on the cell surface membranes (extrinsic pathway) or through a series of cellular events primarily processed at mitochondria (intrinsic pathway). Apoptosis has been shown to be important for tumorigenesis and cancer treatment. Defects in apoptosis can result in the expansion of a population of neoplastic cells. However, because the death of tumor cells induced by chemotherapy and radiotherapy is largely mediated by activation of apoptosis, inhibition of apoptosis will make tumor cells resistant to anti-tumor treatment. Herein, we will review the molecular changes that have the potential to cause apoptotic dysregulation, including activation of antiapoptotic factors (Bcl-2, BCLXL, Bfl1/A1 etc.), inactivation of pro-apoptotic effectors (p53, p53 pathway), and /or reinforcement of survival signals (Survivin, FLIP, NF-κB etc). Furthermore, we will discuss therapeutic intervention and/or strategies that can lower the threshold for apoptosis of tumor cells that could became useful approaches to treat cancer with special emphasis placed on the important priority to develop new cancer therapeutics toward tumor stem cells.
Export Options
About this article
Cite this article as:
Gimenez-Bonafe Pepita, Tortosa Avelina and Perez-Tomas Ricardo, Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells, Current Cancer Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/156800909788166600
DOI https://dx.doi.org/10.2174/156800909788166600 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry Roles of Adrenomedullin in Hypertension and Hypertensive Organ Damage
Current Hypertension Reviews Patients with Prehypertension - Do we have Enough Evidence to Treat them?
Current Vascular Pharmacology The Endothelium and Platelets in Cardiovascular Disease: Potential Targets for Therapeutic Intervention
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Roles of Biogenic Amines in Intestinal Signaling
Current Protein & Peptide Science Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome
Current Vascular Pharmacology Biological Implications of Oxidation and Unidirectional Chiral Inversion of D-amino Acids
Current Drug Metabolism Hypertension in Obstructive Sleep Apnoea
Vascular Disease Prevention (Discontinued) Antimicrobial Drug Interactions in the Critically Ill Patients
Current Clinical Pharmacology Management of Food-Induced Anaphylaxis: Unsolved Challenges
Current Clinical Pharmacology Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacogenomics and Severe Infections: The Role of the Genomes of Both the Host and the Pathogen
Current Pharmacogenomics Calcium-Independent Membrane Damage by Venom Phospholipases A2
Protein & Peptide Letters Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia
Current Alzheimer Research Current Immunotherapies for Renal Cell Carcinoma
Current Molecular Pharmacology Screening, Evaluation, and Early Management of Acute Aortic Dissection in the ED
Current Cardiology Reviews Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition